Disease: anxiety disorders

Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms

mycolabadmin

Psilocybin, a compound from certain mushrooms, is being studied as a potential rapid-acting treatment for severe depression that doesn’t respond to standard antidepressants. Unlike conventional antidepressants that take weeks to work, psilocybin shows promise for producing mood improvements within days. The drug works by activating serotonin receptors in the brain and promoting the growth of new neural connections, though researchers are still working to fully understand how it achieves its antidepressant effects.

Read More »

Further education in psychedelic-assisted therapy – experiences from Switzerland

mycolabadmin

As psychedelic drugs show promise in treating serious mental health conditions like depression and PTSD, there is growing need to train therapists to safely administer these novel treatments. Switzerland’s leading medical association has developed a comprehensive three-year training program that combines classroom learning with hands-on practice to prepare doctors and psychologists. The program faces overwhelming demand, with far more people wanting to train than available spots, highlighting the urgent need for more specialized education programs as these treatments potentially become mainstream medications.

Read More »

Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use

mycolabadmin

Researchers followed 654 people planning to use psychedelics and measured their thinking patterns before and after. They found that delusional thinking actually decreased after use, while about one-third experienced visual effects like seeing trails or intensified colors. However, very few people (less than 1%) found these visual effects bothersome. Younger people, women, and those with psychiatric history were more likely to experience these visual effects.

Read More »

Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings

mycolabadmin

This clinical trial is investigating whether psilocybin (a psychoactive compound found in certain mushrooms) combined with supportive counseling can help people with treatment-resistant obsessive-compulsive disorder. Researchers will give participants two doses of psilocybin while providing non-directive psychological support to help them process their experiences. The study aims to determine whether this approach is safe, tolerable, and effective at reducing OCD symptoms, and to understand the psychological mechanisms that might explain how it works.

Read More »
Scroll to Top